Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 272

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Tumor Mutation Burden as a Biomarker in Resected Non–Small-Cell Lung Cancer

Open access
Devarakonda, Siddhartha, Rotolo, Federico, Tsao, Ming-Sound, Lanc, Irena, Brambilla, Elisabeth, Masood, Ashiq, Olaussen, Ken A., Fulton, Robert, Sakashita, Shingo, McLeer-Florin, Anne, Ding, Keyue, Le Teuff, Gwénaël, Shepherd, Frances A., Pignon, Jean-Pierre, Graziano, Stephen L., Kratzke, Robert, Soria, Jean-Charles, Seymour, Lesley, Govindan, Ramaswamy, Michiels, Stefan·2018·Journal of Clinical Oncology

Abstract

Purpose: The survival benefit with adjuvant chemotherapy for patients with resected stage II-III non–small-cell lung cancer (NSCLC) is modest. Efforts to develop prognostic or predictive biomarkers in these patients have not yielded clinically useful tests. We report findings from the Lung Adjuvant Cisplatin Evaluation (LACE)-Bio-II study, in which we analyzed next-generation sequencing and long-term outcomes data from > 900 patients with early-stage NSCLC treated prospectively in adjuvant landmark clinical trials. We used a targeted gene panel to assess the prognostic and predictive effect of mutations in individual genes, DNA repair pathways, and tumor mutation burden (TMB). Methods: A total of 908 unmatched, formalin-fixed, paraffin-embedded, resected lung cancer tumor specimens were sequenced using a targeted panel of 1,538 genes. Stringent filtering criteria were applied to exclude germline variants and artifacts related to formalin fixation. Disease-free survival, overall survival, and lung cancer—specific survival (LCSS) were assessed in Cox models stratified by trial and adjusted for treatment, age, sex, performance score, histology, type of surgery, and stage. Results: Nonsynonymous mutations were identified in 1,515 genes in 908 tumor samples. High nonsynonymous TMB (> 8 mutations/Mb) was prognostic for favorable outcomes (ie, overall survival, disease-free survival, and LCSS) in patients with resected NSCLC. LCSS benefit with adjuvant chemotherapy was more pronounced in patients with low nonsynonymous TMBs (≤ 4 mutations/Mb). Presence of mutations in DNA repair pathways, tumor-infiltrating lymphocytes, TP53 alteration subtype, and intratumor heterogeneity was neither prognostic nor predictive. Statistically significant effect of mutations in individual genes was difficult to determine due to high false-discovery rates. Conclusion: High nonsynonymous TMB was associated with a better prognosis in patients with resected NSCLC. In addition, the benefit of adjuvant chemotherapy on LCSS was more pronounced in patients with low nonsynonymous TMBs. Studies are warranted to confirm these findings.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2018.78.1963

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 272

Metadata

Authors
Devarakonda, S., Rotolo, F., Tsao, M.-S., Lanc, I., Brambilla, E., Masood, A., Olaussen, K. A., Fulton, R., Sakashita, S., McLeer-Florin, A., Ding, K., Le Teuff, G., Shepherd, F. A., Pignon, J.-P., Graziano, S. L., Kratzke, R., Soria, J.-C., Seymour, L., Govindan, R., & Michiels, S.
Venue
Journal of Clinical Oncology
Published
2018-10-20
Volume
36
Issue
30
Pages
2995-3006
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2885229054
Cited by
272
References
35
FWCI
25.70
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumor Mutation Burden as a Biomarker in Resected Non–Small-Cell Lung Cancer. https://app.cochat.ai/papers/10.1200/jco.2018.78.1963
The paper
Devarakonda, S., Rotolo, F., Tsao, M.-S., Lanc, I., Brambilla, E., Masood, A., Olaussen, K. A., Fulton, R., Sakashita, S., McLeer-Florin, A., Ding, K., Le Teuff, G., Shepherd, F. A., Pignon, J.-P., Graziano, S. L., Kratzke, R., Soria, J.-C., Seymour, L., Govindan, R., & Michiels, S. (2018). Tumor Mutation Burden as a Biomarker in Resected Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2018.78.1963

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.